Your Messages Inbox
Your Article Summary
See Latest ArticlesAmylin Issues Statement in Response to Carl Icahn
Amylin Pharmaceuticals, 04/27/09
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) injection and BYETTA(R) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taros Proprietary Non-Sedating Barbiturate Compound
Taro Pharmaceuticals USA, 12/07/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
b3c newswire, 12/07/09
Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN at 51st ASH Annual Meeting
Allos Therapeutics, 12/07/09
Nplate Data From MDS Studies Presented at ASH
Amgen, 12/07/09
Article Search
Sponsor